Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Invesco Biotechnology & Genome ETF
(NY:
PBE
)
96.40
-2.25 (-2.28%)
Delayed Quote
Updated: 12:34 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Invesco Biotechnology & Genome ETF
Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE?
↗
October 11, 2026
One offers broad diversification at 0.08% cost, while the other targets concentrated biotech growth with higher volatility.
Via
The Motley Fool
Topics
ETFs
PBE vs. RSPH: Is a Biotech ETF or Equal-Weight Healthcare ETF the Better Choice for Investors?
↗
September 15, 2026
PBE offers higher income and stronger returns, while RSPH provides broader diversification with lower costs and drawdown risk.
Via
The Motley Fool
Topics
ETFs
iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy?
↗
September 09, 2026
Broad diversification and lower costs favor iShares, but Invesco's concentrated biotech bet delivered 47% returns in one year—at the cost of steeper drawdowns.
Via
The Motley Fool
Topics
ETFs
MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters
↗
November 05, 2025
Via
Stocktwits
Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion
↗
October 29, 2025
Via
Stocktwits
Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease
↗
September 23, 2025
Via
Stocktwits
Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset?
↗
August 21, 2026
IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.
Via
The Motley Fool
Topics
ETFs
IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?
↗
August 21, 2026
PBE concentrates on 31 companies and offers a higher dividend yield, while IBBQ spreads risk across 251 holdings at a fraction of the cost.
Via
The Motley Fool
Topics
ETFs
VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style?
↗
August 12, 2026
VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.
Via
The Motley Fool
Topics
ETFs
XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?
↗
August 01, 2026
PBE surged 41% in one year but endured a 35% drawdown, while XLV's diversified approach delivered steadier gains with half the volatility.
Via
The Motley Fool
Topics
ETFs
VHT vs. PBE: Which Health Care ETF Is the Better Buy?
↗
July 30, 2026
PBE delivered the better return over the past year, but has experienced greater historical volatility. VHT's more diversified portfolio and rock-bottom fees offer investors a steadier, lower-cost...
Via
The Motley Fool
Topics
ETFs
Why Did MNKD Stock Jump Over 7% In Pre-Market Today?
↗
January 26, 2026
The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus.
Via
Stocktwits
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
↗
September 29, 2025
The U.S. pharmaceutical industry is at the center of a policy maelstrom.
Via
Benzinga
Topics
ETFs
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
↗
February 19, 2024
Biotech stocks, namely those involved with gene editing, have been explosive and could see higher highs with strong catalysts.
Via
InvestorPlace
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
↗
April 13, 2023
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of...
Via
Benzinga
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
↗
April 13, 2023
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.
Via
Benzinga
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
↗
April 12, 2023
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this...
Via
Benzinga
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
↗
April 11, 2023
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating...
Via
Benzinga
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits
↗
April 06, 2023
Via
Benzinga
US Judge Weighs Nationwide Ban On Abortion Pills
↗
March 16, 2023
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is...
Via
Benzinga
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
↗
March 01, 2023
Via
Benzinga
7 Best Biotech Stocks to Buy in July 2022
↗
July 08, 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.
Via
InvestorPlace
Biotech ETFs That Outperformed Last Week
↗
December 20, 2021
Though the broad U.S. market saw a tumultuous ride last week with most of the sectors in red, biotechnology was the biggest gainer.
Via
Talk Markets
A Comprehensive Guide To Genomic ETFs
↗
July 11, 2021
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon...
Via
Talk Markets
5 Top ETFs With Exposure To Biogen
↗
June 07, 2021
Here is a look at five ETFs with large exposure to Biogen shares.
Via
Talk Markets
5 Top ETFs With Exposure To Biogen
↗
June 07, 2021
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that...
Via
Benzinga
3 Biotech Stocks Wall Street Predicts Will Rally By 45% Or More
↗
May 30, 2021
Wall Street analysts expect the biotech industry to grow significantly soon, with the biotech stocks Organogenesis (ORGO), BioDelivery Sciences (BDSI) and Champions Oncology (CSBR) gaining more...
Via
Talk Markets
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit